Variceal Bleeding and Hepatorenal Syndrome Management

Clinical Context

The American Association for the Study of Liver Diseases recommends octreotide as first-line therapy for variceal hemorrhage due to its safety profile, despite terlipressin being the only vasoactive agent proven to reduce bleeding-related mortality in meta-analyses 1, 2
Meta-analyses demonstrate no significant differences between terlipressin and octreotide in mortality, hemostasis rates, early rebleeding, late rebleeding, blood transfusion requirements, or hospital length of stay 2
Both agents achieve comparable bleeding control when combined with endoscopic therapy (77% hemostasis at 5 days with combination therapy versus 58% with endoscopy alone) 2
Terlipressin shows mortality benefit compared to placebo (RR 0.66, 95% CI 0.49-0.88), but direct comparison with octreotide reveals no superiority 3, 2

Adverse events occur 2.39-fold more frequently with terlipressin compared to octreotide 2
Terlipressin causes hyponatremia, myocardial ischemia due to coronary vasoconstriction, abdominal pain, chest pain, diarrhea, and respiratory complications 1, 2
Octreotide's side effects are milder: nausea/vomiting, abdominal pain, headache, hyperglycemia, and hypoglycemia 1, 2

Octreotide: 50 μg IV bolus (can repeat in first hour if bleeding continues), followed by continuous infusion at 50 μg/hour for 2-5 days 1, 4, 2
Terlipressin: 2 mg IV every 4 hours for first 48 hours until bleeding controlled, then 1 mg IV every 4 hours for maintenance, total duration 2-5 days 1, 4, 2

Immediate initiation of vasoactive therapy (octreotide preferred) as soon as variceal bleeding is suspected, even before endoscopic confirmation 1, 2
Prophylactic antibiotics (ceftriaxone 1 g IV every 24 hours for up to 7 days) started simultaneously to reduce mortality, bacterial infections, and rebleeding 3, 4, 2

The American Association for the Study of Liver Diseases recommends terlipressin as the vasoactive drug of choice for hepatorenal syndrome, combined with albumin, accounting for the patient's volume status 1
Terlipressin is the only vasoactive agent with proven efficacy in randomized trials for HRS, reversing type 1 HRS in 33-60% of cases 1
Terlipressin combined with albumin is more efficacious than alternative regimens (midodrine/octreotide or norepinephrine) for HRS reversal 1

Octreotide is the only vasoactive drug available in the United States for variceal bleeding, making it the de facto choice regardless of comparative efficacy 4, 2
Terlipressin was recently FDA-approved specifically for hepatorenal syndrome but remains unavailable or restricted for variceal bleeding in many U.S. centers 2

For Child-Pugh class C or Child-Pugh class B patients with active bleeding despite vasoactive therapy, consider early TIPS placement within 72 hours 4, 2
Patients with MELD >19 or active bleeding during endoscopy may require longer duration of vasoactive therapy (up to 5 days) 2, 6